Related references
Note: Only part of the references are listed.Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
Stephan A. Veltkamp et al.
CLINICAL DRUG INVESTIGATION (2013)
Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
Muhammad Abdul-Ghani et al.
Endocrine Practice (2013)
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial
John P. H. Wilding et al.
ANNALS OF INTERNAL MEDICINE (2012)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
O. Ljunggren et al.
DIABETES OBESITY & METABOLISM (2012)
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
D. Devineni et al.
DIABETES OBESITY & METABOLISM (2012)
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
R. R. Henry et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
Sreeneeranj Kasichayanula et al.
CLINICAL THERAPEUTICS (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects
S. Kasichayanula et al.
DIABETES OBESITY & METABOLISM (2011)
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
S. Sha et al.
DIABETES OBESITY & METABOLISM (2011)
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
S. Kasichayanula et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
K. Strojek et al.
DIABETES OBESITY & METABOLISM (2011)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
M. Obermeier et al.
DRUG METABOLISM AND DISPOSITION (2010)
Sodium-Glucose Co-Transport Inhibitors Progress and Therapeutic Potential in Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
DRUGS (2010)
Exploring Newer Target Sodium Glucose Transporter 2 for the Treatment of Diabetes Mellitus
H. B. Vaidya et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
John P. H. Wilding et al.
DIABETES CARE (2009)
Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents
William N. Washburn
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
George L. Bakris et al.
KIDNEY INTERNATIONAL (2009)
Active sugar transport in health and disease
E. M. Wright et al.
JOURNAL OF INTERNAL MEDICINE (2007)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Phlorizin: a review
JRL Ehrenkranz et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors
J Dudash et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
GLUT1 deficiency and other glucose transporter diseases
JM Pascual et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
IS Wood et al.
BRITISH JOURNAL OF NUTRITION (2003)
A missense mutation in the Na+/glucose cotransporter gene SGLT1 in a patient with congenital glucose-galactose malabsorption:: normal trafficking but inactivation of the mutant protein
M Kasahara et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2001)
Glucose transporters: Structure, function and consequences of deficiency
GK Brown
JOURNAL OF INHERITED METABOLIC DISEASE (2000)
Share Paper
